Squamous Cell Carcinoma of Head and Neck trials in Taiwan: Trial Insights

Filters: Condition: Squamous Cell Carcinoma of Head and Neck Country / region: Taiwan Clear all

108 trials match Source: ClinicalTrials.gov registrations

Top lead sponsors
Category	Trials
AstraZeneca	7
National Taiwan University Hospital	7
Chang Gung Memorial Hospital	6
Novartis Pharmaceuticals	6
AbbVie	5
Pfizer	5
Merck Sharp & Dohme LLC	4
Rakuten Medical, Inc.	3
Astellas Pharma Global Development, Inc.	2
BeiGene	2

Top conditions
Category	Trials
Squamous Cell Carcinoma of Head and Neck	108
Head and Neck Neoplasms	25
Carcinoma, Non-Small-Cell Lung	22
Melanoma	14
Stomach Neoplasms	12
Esophageal Squamous Cell Carcinoma	11
Ovarian Neoplasms	11
Uterine Cervical Neoplasms	11
Esophageal Neoplasms	10
Carcinoma, Renal Cell	9

Trials

Showing 51 to 75 of 108. Each trial links to its page on Pharma Observatory.

A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors NCT04442126Phase 1/2TerminatedNumab Therapeutics AGStarted 2020
Sodium Selenite Supplementation in Patients With Head and Neck Cancer NCT05451576Not applicableUnknown statusChang Gung Memorial HospitalStarted 2020
A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX) NCT04459715Phase 3TerminatedEMD Serono Research & Development Institute, Inc.Started 2020
Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009) NCT04428151Phase 2CompletedMerck Sharp & Dohme LLCStarted 2020
A Study of Sigvotatug Vedotin in Advanced Solid Tumors NCT04389632Phase 1RecruitingSeagen, a wholly owned subsidiary of PfizerStarted 2020
First In Human Study With ABBV-CLS-579 When Given Alone and In Combination In Participants With Locally Advanced Or Metastatic Tumors NCT04417465Phase 1CompletedAbbVieStarted 2020
Ribociclib and Spartalizumab in R/M HNSCC NCT04213404Phase 1Unknown statusNational Taiwan University HospitalStarted 2020
A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010) (KEYNOTE-010) NCT04199104Phase 3CompletedMerck Sharp & Dohme LLCStarted 2020
Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors NCT04215978Phase 1CompletedBeiGeneStarted 2020
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) NCT04198766Phase 1/2RecruitingInhibrx Biosciences, IncStarted 2019
Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors. NCT04152018Phase 1TerminatedPfizerStarted 2019
A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors NCT04032704Phase 2TerminatedSeagen Inc.Started 2019
GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors NCT04083599Phase 1/2Active, not recruitingGenmabStarted 2019
ASP-1929 Photoimmunotherapy (PIT) Study in Recurrent Head/Neck Cancer for Patients Who Have Failed at Least Two Lines of Therapy NCT03769506Phase 3Active, not recruitingRakuten Medical, Inc.Started 2019
Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response to Therapy NCT03719690Phase 2CompletedKura Oncology, Inc.Started 2019
Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors NCT03821935Phase 1Active, not recruitingAbbVieStarted 2019
A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies NCT03829501Phase 1/2TerminatedKymab LimitedStarted 2019
A Study of ASP1951 in Subjects With Advanced Solid Tumors NCT03799003Phase 1TerminatedAstellas Pharma Global Development, Inc.Started 2019
Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab NCT03674567Phase 1/2CompletedRAPT Therapeutics, Inc., a member of the GSK plc group of companiesStarted 2018
A Study of ASP1948, Targeting an Immune Modulatory Receptor as a Single Agent and in Combination With a PD-l Inhibitor (Nivolumab or Pembrolizumab) in Subjects With Advanced Solid Tumors NCT03565445Phase 1CompletedAstellas Pharma Global Development, Inc.Started 2018
Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors NCT03509012Phase 1CompletedAstraZenecaStarted 2018
WGA in Platinum-refractory HNSCC Underwent Nivolumab NCT03917537ObservationalUnknown statusChang Gung Memorial HospitalStarted 2018
Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck Cancer NCT03349710Phase 3CompletedBristol-Myers SquibbStarted 2017
Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304) NCT03358472Phase 3CompletedIncyte CorporationStarted 2017
A Study to Investigate Biomarker Effects of Pre-Surgical Treatment With DNA Damage Repair (DDR) Agents in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC). NCT03022409Phase 1CompletedAstraZenecaStarted 2017

8 more trials match. See them on Pharma Observatory

A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers NCT05544929Completion date change2027-09-01 to 2027-10-05October 22, 2026

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.

Visit Pharma Observatory